# Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Source: https://onco.cc/trials/nct04115306/  
OnCo record `nct04115306` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Phoenix Molecular Designs, active and no longer recruiting.

## Summary

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04115306 by Phoenix Molecular Designs, with 61 participants enrolled, started 2019-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: PMD-026 and fulvestrant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04115306
- Phase: 1/2
- Setting: Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer
- Sponsor: Phoenix Molecular Designs
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT04115306: https://clinicaltrials.gov/study/NCT04115306

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/)

---
JSON: https://onco.cc/api/v1/entities/nct04115306.json